Sanofi Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years.
Sanofi Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents ground-breaking and life-saving advances in medicine. As a Sanofi company, Sanofi Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Sanofi has announced that it will evolve its business with the creation of five Global Business Units. Sanofi Genzyme, the specialty care global business unit of Sanofi, will retain Genzyme’s current portfolio in rare diseases and multiple sclerosis and add Sanofi’s oncology and immunology programs. This new structure was implemented beginning in January 2016.
The acquisition by Sanofi in 2011 has brought a level of professionalism and investment to production systems and facilities that has proved invaluable; including investing 105 million euros (USD 115.47 million) in a new biomanufacturing facility in Lyon, France, that is today exporting to 68 countries, providing more than 200 million euros (USD 220 million) in internal sales and employing 250 people
Contact
33 Boulevard de la Paix, 78100 Saint-Germain-en-Laye, France
Phone:+33 1 30 87 25 25
Web: genzyme.fr
Christian Deleuze reveals the impact of the acquisition by Sanofi in 2011; explains the profitability and global reach of the bio manufacturing facility in Lyon; and tells us that the current system…
The rare disease landscape is becoming increasingly sophisticated, demanding not only scientific innovation but also new approaches to access, evidence generation and patient support. Recordati Rare Diseases has built its…
Sanofi’s new CEO Belén Garijo has taken the reins of a company with healthy growth, but three recent late-stage clinical trial failures and a looming patent cliff for its biggest…
Complementing the Lyon region’s strong industrial footprint is a dense network of hospital facilities, only bettered by Paris on the national level. Across 13 hospitals in the Hospices Civils de…
The Auvergne-Rhône-Alpes region, with Lyon at its heart, is France’s industrial heartland. Hosting over 500,000 manufacturing and manufacturing-related jobs, AURA is also the nation’s top destination the production of biologics,…
European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both…
Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path…
Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
France and Denmark have a rich history of healthcare collaboration, from basic research to clinical trials, as well as major manufacturing investments. What links these two nations, and what are…
France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as…
France’s historical contribution to medical research is almost unparalleled globally, with 13 winners of the annual Nobel Prize for Physiology or Medicine, and even more for Chemistry. Most famously, Louis…
France’s patient advocacy network is one of Europe’s most well-developed and formalised. Patient advocacy groups – including the three featured below – fill in research, care, and support gaps left…
See our Cookie Privacy Policy Here
